Research programme: hepatocyte nuclear factor 4 modulators - Ligand Pharmaceuticals
Latest Information Update: 19 Sep 2006
At a glance
- Originator Ligand Pharmaceuticals
- Developer Eli Lilly; Ligand Pharmaceuticals
- Mechanism of Action Hepatocyte nuclear factor 4 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Metabolic disorders; Type 2 diabetes mellitus